Literature DB >> 21482148

Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality.

Hsuanwen C Huang1, S Samuel Weigt, Ariss Derhovanessian, Vyacheslav Palchevskiy, Abbas Ardehali, Rajan Saggar, Rajeev Saggar, Bernard Kubak, Aric Gregson, David J Ross, Joseph P Lynch, Robert Elashoff, John A Belperio.   

Abstract

BACKGROUND: Pulmonary non-tuberculous mycobacterial (NTM) infection is relatively common after lung transplantation, but the effect on mortality remains undetermined. Herein we describe our experience with pulmonary NTM infection after lung transplantation and hypothesized that non-tuberculous mycobacterial infection after lung transplantation would be associated with increased mortality.
METHODS: We retrospectively evaluated 201 primary lung transplant recipients transplanted between January 2000 and August 2006. Serial bronchoscopies with bronchoalveolar lavage and transbronchial biopsy were performed according to a surveillance protocol and when clinically indicated. The diagnosis NTM infection was established by a positive NTM culture in a bronchoalveolar lavage sample or in at least two separate expectorated sputum samples. NTM infections were further classified as "disease" or "colonization," based on whether or not NTM infection patients developed symptoms and characteristic radiographic findings.
RESULTS: Thirty-six (18%) recipients were diagnosed with pulmonary NTM infection at a median of 97 days post-transplantation: 9 were classified as NTM disease and the remaining 27 as NTM colonization cases. Single lung transplant was a significant risk factor for NTM infection (HR 2.25, p = 0.02). NTM colonization was a risk factor for NTM disease (HR 8.39, p = 0.003). NTM infection significantly increased the risk of death after lung transplantation (HR 2.61, p = 0.001) and persisted in multivariate models controlling for single lung transplant and bronchiolitis obliterans syndrome. The increased risk was seen for both NTM colonization and NTM disease. Among the patients who died, non-NTM infection was a more common contributing factor in the cause of death for the NTM infection group (44% vs 12%, p = 0.04).
CONCLUSIONS: Non-tuberculous mycobacterial infection is common after lung transplantation. NTM colonization and treated acute rejection are risk factors for NTM disease. NTM infection is associated with increased risk of mortality independent of bronchiolitis obliterans syndrome.
Copyright © 2011 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21482148      PMCID: PMC3942162          DOI: 10.1016/j.healun.2011.02.007

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  38 in total

1.  Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation.

Authors:  T J Kroshus; V R Kshettry; K Savik; R John; M I Hertz; R M Bolman
Journal:  J Thorac Cardiovasc Surg       Date:  1997-08       Impact factor: 5.209

2.  Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group.

Authors:  S A Yousem; G J Berry; P T Cagle; D Chamberlain; A N Husain; R H Hruban; A Marchevsky; N P Ohori; J Ritter; S Stewart; H D Tazelaar
Journal:  J Heart Lung Transplant       Date:  1996-01       Impact factor: 10.247

3.  Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation.

Authors:  H Reichenspurner; R E Girgis; R C Robbins; K L Yun; M Nitschke; G J Berry; R E Morris; J Theodore; B A Reitz
Journal:  Ann Thorac Surg       Date:  1996-11       Impact factor: 4.330

4.  Mycobacterial infections in lung transplant recipients.

Authors:  S Kesten; C Chaparro
Journal:  Chest       Date:  1999-03       Impact factor: 9.410

5.  Atypical mycobacteriosis in a lung transplant recipient.

Authors:  S Baldi; M Rapellino; E Ruffini; A Cavallo; M Mancuso
Journal:  Eur Respir J       Date:  1997-04       Impact factor: 16.671

6.  Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation.

Authors:  C A Keller; P T Cagle; R W Brown; G Noon; A E Frost
Journal:  Chest       Date:  1995-04       Impact factor: 9.410

7.  Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients.

Authors:  D E Griffith; W M Girard; R J Wallace
Journal:  Am Rev Respir Dis       Date:  1993-05

8.  Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.

Authors:  D Heng; L D Sharples; K McNeil; S Stewart; T Wreghitt; J Wallwork
Journal:  J Heart Lung Transplant       Date:  1998-12       Impact factor: 10.247

9.  Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome.

Authors:  M A Smith; S Sundaresan; T Mohanakumar; E P Trulock; J P Lynch; D L Phelan; J D Cooper; G A Patterson
Journal:  J Thorac Cardiovasc Surg       Date:  1998-11       Impact factor: 5.209

10.  A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation.

Authors:  J D Cooper; M Billingham; T Egan; M I Hertz; T Higenbottam; J Lynch; J Mauer; I Paradis; G A Patterson; C Smith
Journal:  J Heart Lung Transplant       Date:  1993 Sep-Oct       Impact factor: 10.247

View more
  23 in total

1.  Non-tuberculous mycobacterial infections after solid organ transplantation: a survival analysis.

Authors:  S A Longworth; E A Blumberg; T D Barton; C Vinnard
Journal:  Clin Microbiol Infect       Date:  2014-10-29       Impact factor: 8.067

Review 2.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

3.  Tap Water Avoidance Decreases Rates of Hospital-onset Pulmonary Nontuberculous Mycobacteria.

Authors:  Arthur W Baker; Jason E Stout; Deverick J Anderson; Daniel J Sexton; Becky Smith; Rebekah W Moehring; Kirk Huslage; Christopher J Hostler; Sarah S Lewis
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

4.  Update on nontuberculous mycobacterial infections in solid organ and hematopoietic stem cell transplant recipients.

Authors:  B M Knoll
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

Review 5.  Nontuberculous mycobacteria infections in immunosuppressed hosts.

Authors:  Emily Henkle; Kevin L Winthrop
Journal:  Clin Chest Med       Date:  2014-12-23       Impact factor: 2.878

6.  Tissue-localized immune responses in people with cystic fibrosis and respiratory nontuberculous mycobacteria infection.

Authors:  Don Hayes; Rajni Kant Shukla; Yizi Cheng; Emrah Gecili; Marlena R Merling; Rhonda D Szczesniak; Assem G Ziady; Jason C Woods; Luanne Hall-Stoodley; Namal Pm Liyanage; Richard T Robinson
Journal:  JCI Insight       Date:  2022-06-22

7.  Mycobacterium abscessus Infections in Solid Organ Transplant Recipients: Single-Center Experience in the United States, 2013-2018.

Authors:  Yosuke Ebisu; Yoichiro Natori; Gemma Rosello; Shweta Anjan; Jacques Simkins; Jose F Camargo; Michele I Morris; Octavio V Martinez; Lilian M Abbo
Journal:  Open Forum Infect Dis       Date:  2022-05-18       Impact factor: 4.423

Review 8.  Non-tuberculous Mycobacterial Infections in Thoracic Transplant Candidates and Recipients.

Authors:  Mana Rao; Fernanda P Silveira
Journal:  Curr Infect Dis Rep       Date:  2018-05-12       Impact factor: 3.725

Review 9.  Nontuberculous mycobacterial pulmonary infections.

Authors:  Margaret M Johnson; John A Odell
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

Review 10.  Highlight on advances in nontuberculous mycobacterial disease in North America.

Authors:  Mehdi Mirsaeidi; Maham Farshidpour; Mary Beth Allen; Golnaz Ebrahimi; Joseph O Falkinham
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.